Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SHR-1906 in Healthy Subjects
NCT04986540Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1906 in idiopathic pulmonary fibrosis (IPF) (6 cohorts), sponsored by Hengrui Therapeutics. Primary endpoint: Adverse events at 10 weeks. Started Aug 2021; status: completed.
02
Drugs
SHR-1906
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04986540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04986540.